SCHEMBL14740313

SCHEMBL14740313

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCOCCOCCOC

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 8/20 0.70
▸ ALDH1A1 P00352 3/20 0.52
▸ FAAH O00519 2/20 0.52
▸ CNR2 P34972 2/20 0.52
▸ TRPM8 Q7Z2W7 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KCNK3 O14649 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ TRPV1 Q8NER1 1/20 0.52
▸ MAPT P10636 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15548240 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14740315 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14740218 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14739465 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14739842 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14739797 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14739462 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14739844 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14740217 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8
SCHEMBL14739796 1.00 CNR1 (0.70) CNR1ALDH1A1FAAHCNR2TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059801-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE CATABASIS PHARMACEUTICALS, INC. (US) 2013-03-07 — — US claimed
EP-3210972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) Catabasis Pharmaceuticals, Inc. (US) 2017-08-30 — — EP disclosed
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 — — US disclosed
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 — — US disclosed
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 — — US disclosed
US-20170073305-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE CATABASIS PHARMACEUTICALS, INC. 2017-03-16 — — US disclosed
US-20170073305-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE CATABASIS PHARMACEUTICALS, INC. 2017-03-16 — — US disclosed
US-20170073305-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE CATABASIS PHARMACEUTICALS, INC. 2017-03-16 — — US disclosed
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2015-12-03 — — US disclosed
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2015-12-03 — — US disclosed
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2015-12-03 — — US disclosed
EP-2751071-A2 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE Milne, Jill C. (US) 2014-07-09 — — EP disclosed
US-20130059801-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE CATABASIS PHARMACEUTICALS, INC. (US) 2013-03-07 — — US disclosed
US-20130059801-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE CATABASIS PHARMACEUTICALS, INC. (US) 2013-03-07 — — US disclosed
WO-2013033602-A2 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE MILNE JILL C (US) 2013-03-07 — — WO disclosed
WO-2013033602-A2 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE MILNE JILL C (US) 2013-03-07 — — WO disclosed
US-20130059801-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE CATABASIS PHARMACEUTICALS, INC. (US) 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059801-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE FASN, FADS1, ELOVL5 CNR1 1072/4885ALDH1A1 810/4885FAAH 29/4885
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 CNR1 2881/4885ALDH1A1 3440/4885FAAH 282/4885
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 CNR1 2881/4885ALDH1A1 3440/4885FAAH 282/4885
US-20170073305-A1 FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE FASN, FADS1, ELOVL5 CNR1 1072/4885ALDH1A1 810/4885FAAH 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback